COGT vs RLAY
COGT: A clinical-stage biotechnology company developing precision protein kinase inhibitors for oncology and genetically defined diseases. RLAY: Relay Therapeutics is a precision medicine company leveraging a protein-motion discovery platform to develop targeted therapies for oncology and genetic diseases.
Side-by-side fundamentals
| Metric | COGT | RLAY | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $30.08 | $17.41 | |
| Market cap | $5.2B | $3.8B | |
| Net margin FY2025, SEC XBRL | n/a | -1800.6% | |
| Operating margin FY2025, SEC XBRL | n/a | -1971.6% | |
| ROE FY2025, SEC XBRL | -51.7% | -48.8% | RLAY higher |
| ROA FY2025, SEC XBRL | -35.1% | -44.5% | COGT higher |
| Debt / equity as of 2026-09-03 | 0.37 | 0.00 | RLAY lower |
| Revenue growth (YoY) as of 2026-09-02 | n/a | +23.9% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +123.2% | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.46 | 1.77 | |
| 1-year return as of 2026-10-08 close | +93.1% | +184.9% | RLAY higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.